Premier, Inc.

Good morning and welcome to the Premier, Inc. fiscal 2023 first quarter results and conference call. All participants will be in listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star then one on your telephone keypad. To withdraw your question, please press star then two. Please note this event is being recorded. I would now like to turn the conference over to Angie McCabe, Vice President of Investor Relations. Please go ahead.

Thank you. Welcome to Premier's Fiscal 2023 First Quarter Conference Call. Our speakers this morning are Mike Alkire, Premier's President and CEO, and Craig McCaffin, our Chief Administrative and Financial Officer. Before we get started, I want to remind everyone that our earnings release and the supplemental slides accompanying this conference call are available in the Investors section of our website at investors.premierinc.com. Management's remarks today contain certain forward-looking statements, and actual results could differ materially from those discussed today. These forward-looking statements speak as of today, and we undertake no obligation to update them. Factors that might affect future results are discussed in our filings with the SEC, including our most recent Form 10-K and our Form 10-Q for the quarter, which we expect to file soon. We encourage you to review these detailed safe harbor and risk factor disclosures. Also, where appropriate, we will refer to adjusted or other non-GAAP financial measures, such as free cash flow, to evaluate our business. Reconciliations of non-GAAP financial measures to GAAP financial measures are included in our earnings relief in the appendix of the supplemental slides accompanying this presentation and in our earnings form 8K, which we expect to furnish to the SEC soon. I will now turn the call over to Mike Alkire. Mike?

Thanks, Angie. Good morning, everyone, and thank you for joining us today. This morning, we reported our first quarter results, which were consistent. with our expectations and we are reaffirming our fiscal 2023 guidance, which we introduced at our August earnings call. Our performance reflects continued execution of our strategy to provide value to our members and other customers through our innovative technology-enabled solutions that we expect will result in sustainable, long-term growth and create value for our stakeholders. Through our data and insights that can influence virtually every decision in healthcare, we are demonstrating our value as a trusted partner in helping our members navigate an evolving and challenging environment. This morning, I'll share some highlights from the quarter and the progress we are making towards achieving our long-term growth objectives. Craig will review our financial results and fiscal 2023 outlook in more detail. In our PKI clinical decision support business, we continue to enhance our prior authorization and analytic solutions, among others, to improve the patient, provider, and payer experience. We are expanding our utilization management, or UM, capabilities beyond the way UM is currently delivered. We expect to soon begin scaling a new full-service UM offering that enables providers and payers to leverage medical evidence and partner directly to help ensure the patients receive the most appropriate treatment. This solution will leverage our technology to transform the prior authorization process into one that guides clinicians to the most appropriate evidence-based options for their patients. This clinical decision support technology is embedded into the electronic medical record workflow of the clinician, thereby making it more efficient and less burdensome to the patients provider and payer. Our goal is simple, to accelerate the time it takes for patients to be connected to appropriate therapies and to improve health outcomes. We have also made investments to improve some of our core capabilities, including our clinical surveillance technologies for infection prevention, quality analytics products, and enterprise resource planning technology, among others. These solutions are now being introduced to better serve the growing non-acute market. We are also further expanding our partnerships with pharmaceutical, medical device, and diagnostic companies that leverage Pink AI data and research capabilities for real-world evidence to advance the development and commercialization of critical innovations. On our fiscal 2022 third quarter earnings call, we highlighted the work that Pink AI Applied Sciences is doing to identify patients with idiopathic pulmonary nodules, or IPNs. We are proud that Pink AI Applied Sciences, along with our partners, AstraZeneca and Clinethink, were recently chosen as Biotech Week Boston's 2022 BWB Awards winner for innovative use of technology-enabled healthcare solutions in the digital medicine category. We were recognized for working together to identify patients that have IPNs. As part of our efforts, we reviewed diagnostic scans that were done earlier during the COVID-19 pandemic in the largest health information exchange in the New York market. We identified over 150,000 IPNs of which seven to 10% could be pre-metastatic, early stage lung cancer, and if not for our efforts, could have been overlooked. This most recent recognition further highlights our technology capabilities, and we believe it positions us at the forefront of tech-enabled solutions, adding to our unmatched capabilities and using structured and unstructured data to create analytics to help reduce costs and improve quality. We're also making progress on our strategy to expand into adjacent markets. In October, we completed our previously announced transaction to acquire key assets of TRPN, DirectPay, and Devon Health, or collectively, TRPN. These assets include contracts with more than 900,000 providers across 4.1 million U.S. locations, as well as licenses to cost containment technology. We are focused on integrating the assets into our business and are now developing the acquired provider contracts into a new out of network wrap offering. This new product named Contigo Health ConfigureNet is expected to help improve access to healthcare and reduce the cost to patients as it will provide health plan payers and their health plan members medical claims savings through pre-negotiated discounts with network providers. In addition, Through this asset acquisition, Contigo Health will expand its customer base to include national health plans, specialized insurance providers, and other network companies. Work is underway to build other provider network offerings to meet the specialized needs of the existing and new customers Contigo Health serves. ConfigureNet is also expected to complement and help grow Contigo Health's established health plan administration and centers of excellence lines of business. I am also proud of the way in which we have advanced our environmental, social, and governments, or ESG, efforts over the last year in a manner that supports our strategies to create value for all of our stakeholders. We recently published our 2022 sustainability report highlighting our many practices and initiatives that are aimed at improving healthcare, building trust with our stakeholders, operating responsibly and positively impacting communities, all of which are critical to our mission to improve the health of communities. In addition, we signed the U.S. Department of Health and Human Services Office of Climate Change and Health Equities Climate Pledge, as part of our ongoing commitment to reduce greenhouse gas emissions across the healthcare sector and increase climate resilience. We recognize we have a responsibility to reduce our climate impact, and we are also working alongside healthcare providers and other stakeholders to help support their efforts in reducing their carbon footprint. Together with our vision, mission, and values, ESG practices are guideposts we use to ensure that our strategy delivers long-term sustainable growth while also having a positive global impact. In summary, our business is built on a strong foundation that provides stability and enables growth. We develop and provide innovative technology-enabled solutions to help our members and other customers in the delivery of care. We generate strong cash flow, and we have a flexible balance sheet. We remain focused on our mission and advancing our multi-year strategy to achieve our longer-term goals. I will now turn the call over to Craig McCaslin for a discussion of our operational and financial performance and fiscal 2023 financial guidance. Craig?